Casodex and Malignant neoplasm progression - a phase IV clinical study of FDA data
Malignant neoplasm progression is found among people who take Casodex, especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months.
The phase IV clinical study analyzes which people take Casodex and have Malignant neoplasm progression. It is created by eHealthMe based on reports of 9,845 people who have side effects when taking Casodex from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
9,845 people reported to have side effects when taking Casodex.
Among them, 436 people (4.43%) have Malignant neoplasm progression.
What is Casodex?
Casodex has active ingredients of bicalutamide. It is often used in prostate cancer. eHealthMe is studying from 9,974 Casodex users for its effectiveness, alternative drugs and more.
What is Malignant neoplasm progression?
Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,722 drugs and 1,495 conditions by eHealthMe.
Number of Casodex and Malignant neoplasm progression reports submitted per year:
Time on Casodex when people have Malignant neoplasm progression *:
Gender of people who have Malignant neoplasm progression when taking Casodex*:
Age of people who have Malignant neoplasm progression when taking Casodex *:
Common drugs people take besides Casodex *:
Common side effects people have besides Malignant neoplasm progression *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Casodex and have Malignant neoplasm progression?Check whether Malignant neoplasm progression is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Peng, C. C., Chen, C. Y., Chen, C. R., Chen, C. J., Shen, K. H., Chen, K. C., & Peng, R. Y., "Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model", Scientific reports, 2018 Jan .
Alternative drugs to, pros and cons of Casodex:
- Casodex (9,974 reports)
Malignant neoplasm progression treatments and more:
- Malignant neoplasm progression (80,514 reports)
COVID vaccines that are related to Malignant neoplasm progression:
- Malignant neoplasm progression in Moderna COVID Vaccine
- Malignant neoplasm progression in Pfizer BioNTech Covid Vaccine
- Malignant neoplasm progression in Johnson and Johnson Covid Vaccine
How severe was Malignant neoplasm progression and when was it recovered:
Expand to all the drugs that have ingredients of bicalutamide:
Common drugs associated with Malignant neoplasm progression:
All the drugs that are associated with Malignant neoplasm progression:
- Malignant neoplasm progression (1,722 drugs)
Common conditions associated with Malignant neoplasm progression:
All the conditions that are associated with Malignant neoplasm progression:
- Malignant neoplasm progression (1,495 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on bicalutamide (the active ingredients of Casodex) and Casodex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.